Skip to main content
. 2020 Jul 27;31(2):178–186. doi: 10.1038/s41422-020-0375-9

Fig. 3. Genomic landscape of refractory TNBC.

Fig. 3

a The genomic landscape of the patients in the FUTURE trial. b, c Comparison of mutation frequency between primary and metastatic TNBC (b) and between FUSCC and MSKCC metastatic TNBC (c). MSKCC,  Memorial Sloan-Kettering Cancer Center; FDR, false discovery rate.